Literature DB >> 21816795

Update on external beam radiation therapy in thyroid cancer.

James D Brierley1.   

Abstract

Surgery is the mainstay of treatment for thyroid cancer. The role for external beam radiotherapy (EBRT) as an adjuvant to surgery or as the primary therapy is established in anaplastic thyroid cancer but is controversial in differentiated thyroid cancer and uncertain in medullary thyroid cancer. This update reviews the recent reported success of combining EBRT with taxanes in anaplastic thyroid cancer. Also discussed are the recent reports from large single institutions that support the recommendations of the American and British Thyroid Associations on the use of EBRT in high-risk differentiated thyroid cancer. Further evidence on the role of EBRT in MTC is discussed. The important advances in the delivery of EBRT using intensity-modulated radiation and image-guided radiation that result in more accurate and potentially more effective radiation therapy with less toxicity are also discussed.

Entities:  

Mesh:

Year:  2011        PMID: 21816795     DOI: 10.1210/jc.2011-1109

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Patterns of failure in anaplastic and differentiated thyroid carcinoma treated with intensity-modulated radiotherapy.

Authors:  H Vulpe; J Y Y Kwan; A McNiven; J D Brierley; R Tsang; B Chan; D P Goldstein; L W Le; A Hope; M Giuliani
Journal:  Curr Oncol       Date:  2017-06-27       Impact factor: 3.677

Review 2.  Lenvatinib: A Review in Refractory Thyroid Cancer.

Authors:  James E Frampton
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

3.  Outcome of Treatment for Medullary Thyroid Carcinoma-a Single Centre Experience.

Authors:  Anish Jacob Cherian; Pooja Ramakant; Rekha Pai; Marie Therese Manipadam; S Elanthenral; Anuradha Chandramohan; Julie Hephzibah; David Mathew; Dhukabandhu Naik; Thomas V Paul; Simon Rajaratnam; Nihal Thomas; M J Paul; Deepak Thomas Abraham
Journal:  Indian J Surg Oncol       Date:  2017-12-08

4.  Referral patterns for patients with high-risk thyroid cancer.

Authors:  Megan R Haymart; Mousumi Banerjee; Di Yang; Andrew K Stewart; Jennifer J Griggs; James C Sisson; Ronald J Koenig
Journal:  Endocr Pract       Date:  2013 Jul-Aug       Impact factor: 3.443

5.  Anaplastic thyroid carcinoma.

Authors:  Augusto Taccaliti; Francesca Silvetti; Gioia Palmonella; Marco Boscaro
Journal:  Front Endocrinol (Lausanne)       Date:  2012-07-05       Impact factor: 5.555

6.  Engineering Multi-Walled Carbon Nanotube Therapeutic Bionanofluids to Selectively Target Papillary Thyroid Cancer Cells.

Authors:  Idit Dotan; Philip J R Roche; Miltiadis Paliouras; Elliot J Mitmaker; Mark A Trifiro
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

7.  The role of postoperative adjuvant radiotherapy in the local control in medullary thyroid carcinoma.

Authors:  Aleksandra Kukulska; Jolanta Krajewska; Zofia Kolosza; Ewa Paliczka-Cieslik; Aleksandra Kropinska; Agnieszka Pawlaczek; Zbigniew Puch; Kornelia Ficek; Teresa Lisik; Dorota Sygula; Zbigniew Wygoda; Jozef Roskosz; Jerzy Wydmanski; Barbara Jarzab
Journal:  Endocr Connect       Date:  2019-11-01       Impact factor: 3.335

8.  Case of papillary thyroid cancer presenting with an inoperable cervical mass successfully treated with high-dose radiation therapy.

Authors:  Yasuo Kosugi; Shinichi Ohba; Fumihiko Matsumoto; Keisuke Sasai
Journal:  BMJ Case Rep       Date:  2021-11-30

Review 9.  Radioactive Iodine Therapy and Glucose Tolerance.

Authors:  Roghaieh Samadi; Babak Shafiei; Fereidoun Azizi; Asghar Ghasemi
Journal:  Cell J       Date:  2017-02-22       Impact factor: 2.479

10.  Locoregional disease control after external beam radiotherapy in 91 patients with differentiated thyroid carcinoma and pT4 tumor stage - a single institution experience.

Authors:  Nikola Besic; Marta Dremelj; Gasper Pilko
Journal:  Radiol Oncol       Date:  2018-09-22       Impact factor: 2.991

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.